Avas will commercialize NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. NaMuscla is the first and only licensed product for this indication.

Previous interim data from multiple dosing groups suggested DYNE-101 was working as intended to correct splicing defects, ease myotonia, which is a hallmark DM1 symptom marked by difficulty relaxing ...

Gamstorp specifically excluded clinical myotonia from her syndrome: "The typical inability to relax after a muscle contraction in myotonia congenita is not seen during or between attacks of ...